Ingrid Brown, DO
Internal Medicine · Beavercreek, OHNPI 1952309726
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 131 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $840, more than ten times the $58 reported in 2019.
Across 131 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$383
- Amgen$260
- AbbVie$209
- Lilly USA, LLC$148
- AstraZeneca$133
- Abbott$120
- plus $1K from 25 others
Across 13 payments — averaging $32,563 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$171K
- AstraZeneca$107K
- Merck$78K
- Astrazeneca UK Limited$67K
What the payments were for
- Food & beverage$2,30499%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 22 | $383 |
| Amgen | 16 | $260 |
| AbbVie | 8 | $209 |
| Lilly USA, LLC | 10 | $148 |
| AstraZeneca | 8 | $133 |
| Abbott | 6 | $120 |
| Medtronic | 3 | $100 |
| Bayer | 6 | $94 |
| Johnson & Johnson | 6 | $94 |
| Boehringer Ingelheim | 4 | $78 |
| Aimmune Therapeutics, Inc. | 4 | $73 |
| Xeris Pharmaceuticals, Inc. | 4 | $72 |
| Pfizer | 4 | $66 |
| Dexcom, Inc. | 2 | $61 |
| Corcept Therapeutics | 3 | $58 |
| Antares Pharma, Inc. | 3 | $49 |
| Cequr Corporation | 2 | $39 |
| Merck | 2 | $35 |
| Shire North American Group Inc | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Kowa Pharmaceuticals America, Inc. | 2 | $25 |
| Amarin Pharma, Inc. | 1 | $21 |
| Clarus Therapeutics Inc. | 2 | $20 |
| Zealand Pharma US, Inc. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Tandem Diabetes Care, Inc. | 2 | $17 |
| UCB, Inc. | 1 | $16 |
| Insulet Corporation | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| GSK | 1 | $12 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
How this compares
$2,325 in reported general payments places this provider in the 80th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 89 | $110,978 |
| JardianceEmpagliflozin | 89 | $103,136 |
| FarxigaDapagliflozin Propanediol | 58 | $46,707 |
| CreonLipase/Protease/Amylase | 36 | $42,050 |
| EliquisApixaban | 44 | $40,797 |
| XareltoRivaroxaban | 34 | $33,547 |
| MounjaroTirzepatide | 18 | $21,115 |
| Repatha SureclickEvolocumab | 16 | $17,461 |
| Testosterone | 16 | $11,147 |
| JanuviaSitagliptin Phosphate | 12 | $10,465 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,650 |
| Gabapentin | 144 | $3,629 |
| DuleraMometasone/Formoterol | 11 | $3,616 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $2,836 |
| Esomeprazole Magnesium | 18 | $2,307 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $383 | $110,97889 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $78 | $108,786100 claims |
| AstraZenecaFarxiga | $133 | $46,70758 claims |
| AbbVieCreon, Synthroid | $209 | $43,30562 claims |
| PfizerEliquis | $66 | $40,79744 claims |
| Johnson & JohnsonXarelto | $94 | $33,54734 claims |
| Lilly USA, LLCMounjaro | $148 | $21,11518 claims |
| MerckJanuvia, Dulera | $35 | $14,08123 claims |
| GSKArnuity Ellipta | $12 | $2,14511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Beavercreek
- Hassan MalikAkron$1.7M
- Cyrus HarrisCleveland$726K
- Nina DeepWesterville$614K
- Necklall KhooblallAustintown$448K
- Daniel WeissMentor$406K
- Richard KimDayton$326K
- Marina MagreyCleveland$312K
- Lisa LarkinCincinnati$276K
- Gregg FaimanMayfield Hts$274K
- Vincent MartinCincinnati$261K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.